Glazer W M, Morgenstern H, Jeste D V, Zahner G, Hafez H M, Benarroche C L
Department of Psychiatry, Yale University School of Medicine, New Haven, CT.
Psychoneuroendocrinology. 1987;12(4):289-94. doi: 10.1016/0306-4530(87)90053-9.
A case-control study was done to test the effect of serum dopamine-beta-hydroxylase (DBH) activity on tardive dyskinesia (TD) among 85 schizophrenic outpatients treated with neuroleptics. In contrast to the results of several previous studies, we found no significant association between serum DBH activity and the occurrence or severity of TD, controlling for other TD predictors.
一项病例对照研究旨在检测血清多巴胺-β-羟化酶(DBH)活性对85例接受抗精神病药物治疗的精神分裂症门诊患者迟发性运动障碍(TD)的影响。与之前几项研究的结果相反,在控制其他TD预测因素后,我们发现血清DBH活性与TD的发生或严重程度之间无显著关联。